Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4984623 | 0.79 | MAOA (0.42) | MAOAMAOBALDH1A1MAPTMEN1 | |
| SCHEMBL28792255 | 0.79 | CYP3A4 (0.47) | MAOAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL10044955 | 0.79 | CYP3A4 (0.42) | MAOAMAOBALDH1A1MAPTMEN1 | |
| SCHEMBL119906 | 0.79 | CYP3A4 (0.47) | MAOAMAOBALDH1A1MAPTMEN1 | |
| SCHEMBL19783319 | 0.78 | CYP1A2 (0.41) | MAOAMAOBALDH1A1MAPTMEN1 | |
| SCHEMBL15180071 | 0.75 | CA1 (0.47) | MAOAMAOBALDH1A1MAPTMEN1 | |
| SCHEMBL2461166 | 0.75 | MAOA (0.41) | MAOAMAOBALDH1A1MAPTTHRB | |
| SCHEMBL29739628 | 0.75 | MAOA (0.41) | MAOAMAOBALDH1A1MAPTTHRB | |
| SCHEMBL2274975 | 0.74 | MAOA (0.39) | MAOAMAOBALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL4988758 | 0.74 | ERN1 (0.53) | MAOAMAOBALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630129-B1 | QUINOXALINE DERIVATES | MERCK PATENT GMBH (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-8895559-B2 | Quinoxalines derivatives and pharmaceutical compositions and kits | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8895559-B2 | Quinoxalines derivatives and pharmaceutical compositions and kits | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| WO-2014183300-A1 | VEGFR TYROSINE KINASE INHIBITORS | SUZHOU VIVOTIDE BIOTECHNOLOGIES CO., LTD. (CN) | 2014-11-20 | — | — | WO | disclosed |
| US-20130217670-A1 | QUINOXALINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217670-A1 | QUINOXALINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| CN-103159743-A | Small-molecule inhibitor compound capable of simultaneously inhibiting VEGFR (vascular endothelial growth factor receptor) and EGFR (epidermal growth factor receptor) receptor kinase families and preparation method thereof | CHANGZHOU VELOX PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD | 2013-06-19 | — | — | CN | disclosed |
| WO-2012052102-A1 | QUINOXALINE DERIVATES | MERCK PATENT GMBH (DE) | 2012-04-26 | — | — | WO | disclosed |
| US-6849625-B2 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2005-02-01 | — | — | US | disclosed |
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | US | disclosed |
| EP-1326859-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | AstraZeneca AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030924-A9 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217670-A1 | QUINOXALINE DERIVATIVES | PIK3R5, NQO2, PIK3R1 | MAOA 2057/4885MAOB 1946/4885ALDH1A1 2771/4885 |
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | TOP1, NQO2, ABCC1 | MAOA 955/4885MAOB 1171/4885ALDH1A1 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.